

**OneStep  
 EDDP  
 RapiDip™ InstaTest**

REF 121091-1-21



<b>Sensitivity</b>	<b>100 ng/ml</b>
<b>Specificity</b>	<b>100 %</b>

**INTENDED USE**

The Cortez Diagnostics, Inc. OneStep EDDP RapiCard™ InstaTest is an immunochromatographic one-step test intended for the qualitative determination of methadone's primary metabolite, 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in human urine specimen. The determine limit (cut-off) is 100 ng/ml.

REDDP Test may be used as a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography / Mass spectrometry (GC/MS) has been established as the preferred confirmatory method by the Substance Abuse Mental Health Services Administration (SAMHSA). Clinical consideration and professional judgment should be applied to any test result, particularly when preliminary positive results are indicated.

**SUMMARY AND EXPLANATION**

2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) is the primary metabolite of methadone. Methadone is a controlled substance and is used for detoxification and maintenance of opiate dependant patients. Patients on methadone maintenance may exhibit methadone (parent) levels that account for 5-50% of the

dosage and 3-25% of EDDP in urinary excretion during the first 24 hours. The detection of EDDP is more beneficial than traditional methadone screening, in that EDDP exists only in urine from individuals that ingested methadone. The tampering of specimens by spiking the urine with methadone can be prevented.

**TEST PRINCIPLE**

EDDP Test is based on the principle of the highly specific immunochemical reactions of antibodies and antigens, which are used for the analysis of specific compounds in human urine. The drug-protein conjugate competes for limited antibody binding sites with drugs that may be present in the urine. When drug is present in the urine specimen, it competes with drug protein conjugate for the limited amount of antibody-dye conjugate. If the amount of free drug is equal to or greater than the cutoff, it will prevent binding of the drug protein conjugate to the antibody-dye conjugate. Therefore, a positive urine specimen will not show a colored band on the test line zone, indicating a positive result, while the presence of a colored band indicates a negative result.

A control line is present in the test window to serve as procedural control. This colored band should always appear on the control line zone if the test device is stored in good condition and the test is performed properly.

**SPECIMEN COLLECTION AND PREPARATION**

It is required that approximately 150 µl of sample for each test. Fresh urine specimens do not need any special handling or treatment. Specimens should be collected in a clean, dry, plastic or glass container. If the assay is not performed immediately, urine specimen may be refrigerated at 2-8oC or frozen up to 7 days. Specimens should be thawed and brought to room temperature before testing. Urine specimens exhibiting a large amount of precipitate or turbidity should be centrifuged or allowed to settle before testing. Avoid contact with skin by wearing gloves and proper laboratory attire.

**MATERIALS AND COMPONENTS**

**Materials provided with the test kits**

1. Instructions for use.
2. EDDP test device. The amount of each coated antigen and/or antibody on the strip is less than 1.0 mg for antigen conjugate and is less than 1.0 mg for goat anti-mouse IgG antibody.
3. Test zone: contains EDDP bovine protein antigen conjugates.
4. Control zone: contains Goat anti-mouse IgG antibody.
5. Conjugate pad: contains mice monoclonal anti-EDDP antibody.

**Materials required but not provided**

1. Urine collection container.
2. Timer or clock.

**ASSAY PROCEDURE**

1. Bring all materials and specimens to room temperature.
2. Remove the test strip from the sealed foil pouch.
3. Dip the strip into the urine specimen with the arrow pointing toward the sample. The sample level should not be higher than the arrow pointed maximum line.
4. Hold the strip in the urine until a reddish color appears at the test area (approximately 20 seconds).
5. Withdraw the strip and place it face up on a clean, non-absorptive surface or leave the strip in urine if the urine level is not higher than arrow pointed maximum line.
6. Read the results at 5 minutes after adding the sample.  
*Do not interpret the result after 10 minutes.*

**RESULTS**

- **Negative:** Two colored bands form. The appearance of two colored bands, one in test line zone and the other in control line zone, indicates negative results. The negative result indicates that the EDDP concentration in the specimen is either zero or less than cut-off level.
- **Positive:** One colored band forms. One colored band appears in control line zone. No colored band is found in test line zone. This is an indication that the EDDP level in the specimen is above the cut-off level.
- **Invalid:** If there is no colored band in control line zone, the test result is invalid. Retest the sample with a new device.



*Note: A borderline (+/-) in test line zone should be considered negative result.*

## QUALITY CONTROL

Good Laboratory Practice recommends the daily use of control materials to validate the reliability of device. Control materials should be assayed as clinical specimen and challenging to the assay cutoff concentration, e.g., 25% above and below cutoff concentration. If control values do not fall within establish range, assay results are invalid. Control materials which are not provided with this test kit are commercially available.

The Rapid Drugs of Abuse Test provides a built-in process control with a different antigen/antibody reaction at the control region (C). This control line should always appear regardless the presence of drug or metabolite. If the control line does not appear, the test device should be discarded and the obtained result is invalid. The presence of this control band in the control region serve as 1) verification that sufficient volume is added, 2) that proper flow is obtained.

## PERFORMANCE CHARACTERISTICS

Cortez EDDP Test	(-)		(+) GC/MS POS (greater than + 25% C/O)		Percent agreement with GC/MS
	Negative By GC/MS	Near Cut-off NEG (between -25% and C/O)	Near Cut-off N POS (between -25% and C/O)	GC/MS POS (greater than + 25% C/O)	
Positive	0	2	8	70	97.5 %
Negative	70	8	2	0	97.5 %
Total	70	10	10	70	<b>N =160</b>

### A. Accuracy

The accuracy of the methadone metabolite (EDDP) test was evaluated in comparison to GC/MS method at a cut-off of 100 ng/mL EDDP. One hundred and sixty (160) specimens with EDDP concentration confirmed by GC/MS were evaluated.

Positive % agreement: 97.5, Negative % agreement: 97.5.

Four (4) specimens were found discrepant between the EDDP and GC/MS method. When compared those data, 100% (4 out of 4) of the discrepancy specimens were found between -25% cut-off and +25% cut-off concentration (75 – 125 ng/ml).

### B. Sensitivity

The cut-off concentration (sensitivity level) EDDP test is determined to be 100 ng/mL of EDDP.

### C. Precision

The precision study was performed by three individuals observing the test result to determine the random error of visual interpretation. The test results were found to have no significant differences between the three observers.

Device	Control Con. ng/ml	No. of Tested	No. of negative			No. of borderline *			No. of positive		
			1*	2*	3*	1*	2*	3*	1*	2*	3*
	50	120	40	40	40						
	75	120	31	28	30	9	12	10			
EDDP	100	120				11	14	10	29	26	30
	125	120				1	1	2	39	39	38
	150	120							40	40	40

The precision study was performed by three individuals observing the test results to determine the random error of visual interpretation. The results were found to have no significant differences between three observers.

### D. Specificity

The specificity for EDDP test was tested by adding various drugs, drug metabolites, and other compounds that are likely to be present in urine. All compounds were prepared in drug-free normal human urine.

#### 1. Interference Testing

The EDDP test performance at cut-off level is not affected when pH and Specific Gravity ranges of urine specimen are at 4.5 to 9.0 and 1.005 to 1.035.

**The following substances were tested and confirmed not to interfere with EDDP test at the listed concentrations.**

Glucose 2000 mg/dl

Human albumin 2000 mg/dl  
 Human hemoglobin 10 mg/dl  
 Urea 4000 mg/dl  
 Uric acid 10 mg/dl

### 2. Specificity

The following table lists compounds that are detected by Cortez BAR test which produced positive results when tested at levels equal or greater than the concentrations listed below:

Compounds	Cut-off (ng/ml)	Cross reactivity (%)
EDDP	100 ng/m/	100 %
EMDP	200,000 ng/ml	0.05 %
Methadone	500,000 ng/ml	0.02%

Each listed substance that commonly found in the urine was evaluated and indicated negative result at concentration of 100 µg/ml.

Acetaminophen	4-Acetamidophenol	Acetylsalicylic Acid
Amitriptyline	Amobarbital	Amphetamine
Aspartame	Ascorbic acid	Atropine
Camphor	Chloroquine	Chlopheniramine
Deoxyephedrine	Dextromethorphan	Digitoxin
Diphenhydramine	Egonine	Egonine methyl ester
Epinephrine	Gentisic	Guaiacol glycer ester
Hydrochlorothiazide	Homatrophine	Imipramine
Isoproterenol	Ketamine	Lidocaine
Methamphetamine	3,4 ±MDMA	Methaqualone
Neomycin	Niacinamide	Oxazepam
Penicillin G	Phenacyclidine	Phenylethylamine-α
Promethazine	Pseudoephedrine	Quinine antidine
Tetrahydrozoline	Theophylline	11- nor-Δ <sup>8</sup> -THC-9-COOH ( 10 µg/ml)
Tryptophan	Tyramine	Thioridazine
Amikacin		
Alterenol		
Caffeine		
Cortisone		
Digoxin		
Ephedrine		
Histamine		
Ibuprofen		
Meperidine		
Methylphenidate		
Perphenazine		
Phenylpropanolamine		
Tetracycline		
Trifluoperazine		

**LIMITATION OF PROCEDURE**

The assay is designed for use with human urine only. A positive result with any of the tests indicates only the presence of a drug/metabolite and does not indicate or measure intoxication. There is a possibility that technical or procedural error as well other substances in certain foods and medicines may interfere with the test and cause false results. Please refer "SPECIFICITY" section for lists of substances that will produce either positive results, or that do not interfere with test performance. If a drug/metabolite is found present in the urine specimen, the assay does not indicate frequency of drug use or distinguish between drug of abuse and certain foods and medicines.

**EXPECTED VALUES**

The Cortez Diagnostics, Inc. OneStep Rapid EDDP test is a qualitative assay, which only identifies the EDDP concentration in human urine is higher or lower than the cut-off concentration. The exact concentration of the EDDP cannot be determined by this assay. The test is intended to distinguish a negative result from a presumptive positive result. All positive results must be confirmed by using an alternate method, preferably GC/MS.

**PRECAUTION**

1. For in vitro diagnostic and forensic use only.
2. Do not use the product beyond the expiration date.
3. Handle all specimens as potentially infectious.
4. Humidity sensitive product, do not open foil pouch until it is ready to be tested.
5. Use a new urine specimen cup for each sample to avoid cross contamination.


**STORAGE**


1. The product is Humidity sensitive and do not open foil pouch until it is ready to be tested.
2. The device should be stored at 4-30°C and is effective until the expiration date stated on the package.

**REFERENCES**

1. Urine Testing for Drugs of Abuse, NIDA Research Monograph 73, (1986).
2. Critical Issues in Urinalysis of Abused Substances: Report of the Substance Abuse Testing committee, clinical Chemistry, 34(3), 617 (1988).
3. Blum, K., Handbook of Abusable drugs, Gardener Press, Inc., New York, NY, 1st Ed., (1984).
4. Baselt, R.C., Disposition of Toxic Drugs and Chemicals in Man, 3rd Ed., Chicago, IL. Year Book Medical Publishers Inc., 780-783, (1990).
5. Mandatory Guidelines for Federal Workplace Drug Testing Programs, Fed. Reg.53(69):11970-89 (1988)
6. Stewart, D.J., et. al.: Cocaine and norcocaine hydrolysis by liver and serum esterase. Clin. Pharmacol. Ther., 25:464-468 (1978).
7. Goldman FR and Thistel CI, Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict. 13:855-862 (1978).
8. Brodin K. et al., Monitoring of methadone does intake. The Drug Monit. 19:591 (1997).

**ISO 13485  
ISO 9001**



 **Diagnostic Automation/  
Cortez Diagnostics, Inc.**  
**21250 Califa Street, Suite 102 and 116  
Woodland Hills, California 91367 USA**

<b>Date Adopted</b>	<b>2016-01-25</b>
<b>REF</b> 121091-1	<b>CORTEZ- OneStep EDDP RapiDip™ InstaTest</b>
<b>EC</b> <b>REP</b>	<b>CEpartner4U, Esdoornlaan 13, 3951DB Maarn. The Netherlands.</b> <a href="http://www.cepartner4u.eu">www.cepartner4u.eu</a>
Revision B Date: 2012-08-01	